At a glance
ClinicalIndex Comparison RecordN/ACompleted· 503 enrolled
Drug / intervention
Fragmin® (Dalteparin Sodium)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin® (Dalteparin Sodium) In Patients Undergoing Major Orthopedic Surgery
In Brief
An observational study evaluating Fragmin® (Dalteparin Sodium) for Venous Thromboembolism. Completed, enrolled 503 participants.
Detailed Summary
The objective of this study is to observe the safety, tolerability, and compliance in the use of Fragmin® for prolonged thromboprophylaxis in post-surgery high-risk orthopedic patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsVenous Thromboembolism
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2010
Enrollment StartMar 2010
Primary CompletionFeb 2011
TodayJul 2026
First PostedJan 12, 2010
Enrollment StartMar 1, 2010
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.5 years ago
Interventions
Fragmin® (Dalteparin Sodium)drug
Administered per prescribing physician